PDF herunterladen
Thromb Haemost 1999; 81(04): 664-665
DOI: 10.1055/s-0037-1614547
Letters to the Editor
Schattauer GmbH

Increased Heart Rate and Haemostatic Balance Disorders Pre-exist the Established Hypertension

Thomas K. Makris
1   From the Athens University, Medical school and Dept. of Cardiology, 2nd Reg BTC, Haemostasis Lab.,“LAIKON” General Hospital, Athens, Greece
,
George Stavroulakis
1   From the Athens University, Medical school and Dept. of Cardiology, 2nd Reg BTC, Haemostasis Lab.,“LAIKON” General Hospital, Athens, Greece
,
Antonios N. Hatzizacharias
1   From the Athens University, Medical school and Dept. of Cardiology, 2nd Reg BTC, Haemostasis Lab.,“LAIKON” General Hospital, Athens, Greece
,
Panagiota G. Krespi
1   From the Athens University, Medical school and Dept. of Cardiology, 2nd Reg BTC, Haemostasis Lab.,“LAIKON” General Hospital, Athens, Greece
,
Caterina G. Tsoukala
1   From the Athens University, Medical school and Dept. of Cardiology, 2nd Reg BTC, Haemostasis Lab.,“LAIKON” General Hospital, Athens, Greece
,
Filippos K. Triposkiadis
1   From the Athens University, Medical school and Dept. of Cardiology, 2nd Reg BTC, Haemostasis Lab.,“LAIKON” General Hospital, Athens, Greece
,
Titika Mandalaki
1   From the Athens University, Medical school and Dept. of Cardiology, 2nd Reg BTC, Haemostasis Lab.,“LAIKON” General Hospital, Athens, Greece
,
Michael Kyriakidis
1   From the Athens University, Medical school and Dept. of Cardiology, 2nd Reg BTC, Haemostasis Lab.,“LAIKON” General Hospital, Athens, Greece
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
09. Dezember 2017 (online)

    Lizenzen und Reprints

 

 

  • References

  • 1 Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 1990; 227: 273-8.
    CrossrefPubMedGoogle Scholar
  • 2 Makris Th Tsoukala C, Krespi P, Hatzizacharias A, Gialeraki A, Papargyriou J, Votteas V, Mandalaki T. Haemostasis balance disorders in patients with essential hypertension. Thromb Res 1998; 88: 99-107.
    PubMedGoogle Scholar
  • 3 Lip GH, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80: 1566-71.
    CrossrefPubMedGoogle Scholar
  • 4 Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Haemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscl Thromb Vasc Biol 1997; 17: 3321-5.
    CrossrefPubMedGoogle Scholar
  • 5 Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997; 11: 519-27.
    PubMedGoogle Scholar
  • 6 Giblum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease and death. The NHANES I Epidemiologic Follow up study. Am Heart J 1991; 121: 172-177.
    CrossrefPubMedGoogle Scholar
  • 7 Nordrehaug Mo R, Omrik P, Lung-Johansen P. The Bergen blood pressure study: prehypertensive changes in cardiac structure and function in offspring of hypertensive families. Blood Pressure 1995; 4: 16-22.
    CrossrefPubMedGoogle Scholar
  • 8 Endre T, Mattiason I, Berntorp E, Berglud G, Hulthen U. Coagulation and fibrinolytic factors in normotensive hypertension-prone men. J Hypertens 1996; 14: 629-34.
    CrossrefPubMedGoogle Scholar
  • 9 Lee AJ, Lowe GD, Woodward M, Pedro HT. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study. Br Heart J 1995; 69: 338-42.
    PubMedGoogle Scholar
  • 10 Henry M, Tregonet DA, Alesi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan Vague I. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscl Thromb Vasc Biol 1998; 18: 84-91.
    CrossrefPubMedGoogle Scholar